永顺生物
(839729)
| 流通市值：7.52亿 | | | 总市值：25.56亿 |
| 流通股本：8042.50万 | | | 总股本：2.73亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 200,361,538.4 | 119,176,173.44 | 66,495,478.87 | 314,282,861.48 |
| 营业收入 | 200,361,538.4 | 119,176,173.44 | 66,495,478.87 | 314,282,861.48 |
| 二、营业总成本 | 171,882,299.31 | 101,264,705.6 | 57,569,882.86 | 258,618,527.57 |
| 营业成本 | 85,158,653.22 | 49,233,656.06 | 28,621,261.44 | 129,407,847.65 |
| 税金及附加 | 1,531,980.55 | 959,441.66 | 507,383.21 | 2,238,473.81 |
| 销售费用 | 43,690,401.29 | 26,632,345.33 | 14,842,617.78 | 61,748,330.69 |
| 管理费用 | 27,037,535.93 | 16,197,733.88 | 9,239,835.06 | 43,141,693.47 |
| 研发费用 | 15,616,737.4 | 9,793,094.43 | 5,350,715.65 | 25,679,787.92 |
| 财务费用 | -1,153,009.08 | -1,551,565.76 | -991,930.28 | -3,597,605.97 |
| 其中:利息费用 | 622,688.72 | 376,822.73 | 156,978.15 | 1,908,682.18 |
| 其中:利息收入 | 2,064,731.92 | 1,860,619.51 | 1,123,276.96 | 5,620,329.1 |
| 加:公允价值变动收益 | 283,903.39 | 324,266.06 | 42,234.34 | 1,867,816.87 |
| 加:投资收益 | 5,972,917.31 | 3,411,320.09 | 1,608,775.65 | 5,274,819.48 |
| 资产处置收益 | 206,213.59 | 206,213.59 | - | 131,628.39 |
| 资产减值损失(新) | -5,837,805.15 | -5,697,619.19 | -2,878,158.57 | -2,841,005 |
| 信用减值损失(新) | 556,040.58 | -818,910 | 413,757.44 | -6,601,752.05 |
| 其他收益 | 2,756,135.7 | 1,945,116.63 | 1,248,740.12 | 7,607,195.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 32,416,644.51 | 17,281,855.02 | 9,360,944.99 | 61,103,036.71 |
| 加:营业外收入 | 152,531.44 | 132,237.44 | 75,948.14 | 5,044,731 |
| 减:营业外支出 | 40,275.36 | 39,975.42 | 16,391.83 | 866,920.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 32,528,900.59 | 17,374,117.04 | 9,420,501.3 | 65,280,847.31 |
| 减:所得税费用 | 3,565,430.4 | 1,840,218.63 | 1,045,989.79 | 7,222,103.06 |
| 六、净利润 | 28,963,470.19 | 15,533,898.41 | 8,374,511.51 | 58,058,744.25 |
| 持续经营净利润 | 28,963,470.19 | 15,533,898.41 | 8,374,511.51 | 58,058,744.25 |
| 归属于母公司股东的净利润 | 28,963,470.19 | 15,533,898.41 | 8,374,511.51 | 58,058,744.25 |
| (一)基本每股收益 | 0.11 | 0.06 | 0.03 | 0.21 |
| (二)稀释每股收益 | 0.11 | 0.06 | 0.03 | 0.21 |
| 九、综合收益总额 | 28,963,470.19 | 15,533,898.41 | 8,374,511.51 | 58,058,744.25 |
| 归属于母公司股东的综合收益总额 | 28,963,470.19 | 15,533,898.41 | 8,374,511.51 | 58,058,744.25 |
| 公告日期 | 2024-10-25 | 2024-08-16 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |